UOC
BLCM

UBS O'Connor’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

UBS O'Connor’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-4,524
Closed -$1.04M – 876
2014
Q4 		$1.04M Buy
+4,524
New +$970K 0.02% 353

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS O'Connor's BLCM Position: Q1 2015 in Review

UBS O'Connor sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2015, closing a stake of 4,524 shares — an estimated $1.04M sold.

UBS O'Connor first reported a position in BLCM in Q4 2014 and held it in 1 quarter. The position peaked at $1.04M in Q4 2014. 71 funds tracked by Wall St. Rank hold BLCM as of Q1 2015.

  • UBS O'Connor reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • UBS O'Connor sold 4,524 Bellicum Pharmaceuticals, Inc. shares in Q1 2015, an estimated $1.04M.
  • UBS O'Connor first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • UBS O'Connor's Bellicum Pharmaceuticals, Inc. position peaked at $1.04M in Q4 2014.
  • 71 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2015.

Based on UBS O'Connor's 13F filing for Q1 2015, filed 14 May 2015.